AstraZeneca will invest $2.5bn (£1.9bn) in research and manufacturing in Beijing, as the pharmaceutical company tries to move past recent controversies including ditching plans for the expansion of a UK vaccine plant and the detention of top executives in China.
The investment will be staggered over the next five years as part of a “strategic partnership” with the city’s authorities and includes agreements with three local biotech companies.
